Cover Image

市場進入的課題:HIV (美國)

Market Access Impact: HIV (US)

出版商 FirstWord 商品編碼 358491
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:HIV (美國) Market Access Impact: HIV (US)
出版日期: 2016年04月01日 內容資訊: 英文



  • 各種障礙對打入市場的影響
    • 醫生最大量開處方的品牌為何?
    • 受各種障礙影響的處方箋數為何?
    • 哪個障礙最影響大?
  • 障礙對各品牌的影響
    • 醫生對各品牌的處方數為何?不打算再開處方的數為何?
    • 醫生不開處方的理由為何?替代其開處方的藥物為何?
    • 被競爭品牌奪走的佔有率有多少?


  • Evotaz
  • Intelence
  • Isentress
  • Selzentry
  • Stribild
  • Triumeq
  • Truvada
  • Viread
Product Code: 596200649

Can prescription barriers help other HIV brands catch up to the runaway market leader?

In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the deciding factor in close races for 2nd and 3rd place?

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Evotaz, Intelence, Isentress, Selzentry, Stribild, Triumeq, Truvada, and Viread.

You'll find out which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Get Answers to Key Questions about HIV Drug Brands

  • Evotaz (atazanavir/cobicistat; BMS) : Does Evotaz lose more market share because of pricing or formulary availability?
  • Intelence (etravirine; Janssen Biotech) : Does Intelence lose more market share to Isentress or Stribild?
  • Isentress (raltegravir; Merck & Co.) : Does Isentress gain more market share when competing brands are too expensive or when they're not available on formularies?
  • Selzentry (maraviroc; ViiV Healthcare) : Which market barriers cost Selzentry the most market share. How much share would it gain if they didn't exist?
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead) : Do more doctors prescribe Stribild or Triumeq? Which brand has more market share?
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare) : Only two FDCs saw a net share gain because of barriers. Is Triumeq one of them?
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead) : Is Truvada taking more market share from Stribild or is it the other way 'round?
  • Viread (tenofovir disoproxil fumarate; Gilead) : Only one monotherapy saw a net share gain because of barriers. Is it Viread?

Top Takeaways

  • Clear market leader: The most prescribed brand not only has a 12% market share advantage, it also sees twice the barrier-related share gain (net) of its nearest rival.
  • Only three brands benefit from barriers: These brands all saw a net gain in market share, while the other five saw net losses.
  • Brand awareness is high: 97% or greater among doctors surveyed for any given brand.
  • Barrier effect is uneven: The number of doctors who experience the top 3 market barriers varies greatly from brand to brand.
  • FDCs somewhat more prescribed: Although nearly all surveyed brands are widely prescribed, three of the four most prescribed brands are fixed-dose combinations.
  • Cost barriers have the greatest impact: Barriers related to pricing and formulary availability affect more prescriptions than any others.
  • Barrier effect significant for "other" brands: Taken together, "other" brands have a greater market share than 5 of the surveyed brands, and see the third biggest net gain due to barriers.

Exploring Market Access Issues

Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 Medical Oncologists in the US, chosen from the largest community of validated physicians in the world

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between March 2nd and 9th, 2016.

Back to Top